Literature DB >> 29944930

Recurrence of tuberculosis among patients following treatment completion in eight provinces of Vietnam: A nested case-control study.

Jessica Rutledge Bruce Musselman Bestrashniy1, Viet Nhung Nguyen2, Thi Loi Nguyen1, Thi Lieu Pham1, Thu Anh Nguyen1, Duc Cuong Pham1, Le Phuong Hoa Nghiem1, Thi Ngoc Anh Le2, Binh Hoa Nguyen3, Kim Cuong Nguyen4, Huy Dung Nguyen5, Tran Ngoc Buu1, Thi Nhung Le1, Viet Hung Nguyen1, Ngoc Sy Dinh2, Warwick John Britton6, Guy Barrington Marks7, Greg James Fox8.   

Abstract

BACKGROUND: Patients completing treatment for tuberculosis (TB) in high-prevalence settings face a risk of developing recurrent disease. This has important consequences for public health, given its association with drug resistance and a poor prognosis. Previous research has implicated individual factors such as smoking, alcohol use, HIV, poor treatment adherence, and drug resistant disease as risk factors for recurrence. However, little is known about how these factors co-act to produce recurrent disease. Furthermore, perhaps factors related to the index disease means higher burden/low resource settings may be more prone to recurrent disease that could be preventable.
METHODS: We conducted a case-control study nested within a cohort of consecutively enrolled adults who were being treated for smear positive pulmonary TB in 70 randomly selected district clinics in Vietnam. Cases were patients with recurrent TB, identified by follow-up from the parent cohort study. Controls were selected from the cohort by random sampling. Information on demographic, clinical and disease-related characteristics was obtained by interview. Treatment information was extracted from clinic registries. Logistic regression, with stepwise selection, was used to develop a fully adjusted model for the odds of recurrence of TB.
RESULTS: We recruited 10,964 patients between October 2010 and July 2013. Median follow-up was 988 days. At the end of follow-up, 505 patients (4.7%) with recurrence were identified as cases and 630 other patients were randomly selected as controls. Predictors of recurrence included multidrug-resistant (MDR)-TB (adjusted odds ratio 79.6; 95% CI: 25.1-252.0), self-reported prior TB therapy (aOR=2.5; 95% CI: 1.7-3.5), and incomplete adherence (aOR=1.9; 95% CI 1.1-3.1).
CONCLUSIONS: Index disease treatment history is a leading determinant of relapse among patients with TB in Vietnam. Further research is required to identify interventions that will reduce the risk of recurrent disease and enhance its early detection within high-risk populations. Crown
Copyright © 2018. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Active tuberculosis; Contact investigation; Relapse; Risk factors; Screening; Tuberculosis; Tuberculosis epidemiology

Mesh:

Substances:

Year:  2018        PMID: 29944930     DOI: 10.1016/j.ijid.2018.06.013

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  11 in total

Review 1.  Closing gaps in the tuberculosis care cascade: an action-oriented research agenda.

Authors:  Ramnath Subbaraman; Tulip Jhaveri; Ruvandhi R Nathavitharana
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-01-11

Review 2.  All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era.

Authors:  Helen R Stagg; Mary Flook; Antal Martinecz; Karina Kielmann; Pia Abel Zur Wiesch; Aaron S Karat; Marc C I Lipman; Derek J Sloan; Elizabeth F Walker; Katherine L Fielding
Journal:  ERJ Open Res       Date:  2020-11-02

3.  Effect of Health Education Combined with Dietary Guidance on Nutritional Indicator, Immune Level, and Quality of Life of Patients with Pulmonary Tuberculosis.

Authors:  Baojuan Hu; Guoxia Ren; Lin Zhao
Journal:  Comput Math Methods Med       Date:  2021-09-29       Impact factor: 2.238

4.  Risk factor for 31-day unplanned readmission to hospital in patients with pulmonary tuberculosis in China.

Authors:  Jing Cao; Shengpeng Liu; Juhua Huang
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

5.  Classifying recurrent Mycobacterium tuberculosis cases in Georgia using MIRU-VNTR typing.

Authors:  Nino Maghradze; Levan Jugheli; Sonia Borrell; Nestani Tukvadze; Rusudan Aspindzelashvili; Zaza Avaliani; Klaus Reither; Sebastien Gagneux
Journal:  PLoS One       Date:  2019-10-18       Impact factor: 3.240

6.  Tuberculosis recurrences and predictive factors in a vulnerable population in Catalonia.

Authors:  Sílvia Brugueras; Vinicio-Israel Molina; Xavier Casas; Yoel-Domingo González; Nuria Forcada; Dora Romero; Anna Rodés; Maria-Neus Altet; José Maldonado; Mario Martin-Sánchez; Joan A Caylà; Àngels Orcau; Cristina Rius; Joan-Pau Millet
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

7.  Tuberculosis treatment outcome among patients treated in public primary healthcare facility, Addis Ababa, Ethiopia: a retrospective study.

Authors:  Atalay Mulu Fentie; Tadesse Jorgi; Tamrat Assefa
Journal:  Arch Public Health       Date:  2020-03-10

8.  Mortality and risk of tuberculosis among people living with HIV in whom TB was initially ruled out.

Authors:  Juan Ignacio García; Edson Mambuque; Dinis Nguenha; Faustino Vilanculo; Charfudin Sacoor; Victor Guillermo Sequera; Manuel Fernández-Quevedo; Maxime Leroux-La Pierre; Helio Chiconela; Luis A Faife; Durval Respeito; Belén Saavedra; Tacilta Nhampossa; Elisa López-Varela; Alberto L Garcia-Basteiro
Journal:  Sci Rep       Date:  2020-09-22       Impact factor: 4.379

9.  Risk factors associated with pulmonary tuberculosis relapses in Cali, Colombia.

Authors:  Cindy Córdoba; Paola A Buriticá; Robinson Pacheco; Anyela Mancilla; Augusto Valderrama-Aguirre; Gustavo Bergonzoli
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935

10.  Acetylator Status Among Newly Diagnosed and Recurrent Tuberculosis Patients from Kupang, Eastern Part of Indonesia.

Authors:  Edhyana Sahiratmadja; Ika Agus Rini; Simeon Penggoam; Afandi Charles; Ani Melani Maskoen; Ida Parwati
Journal:  Pharmgenomics Pers Med       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.